The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
The Role of Epitranscriptomics in Development and Disease (R01, R21 - Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.
Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-18-831, which uses the R21 grant mechanism.
Application Due Dates: November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021
PAR-18-830 Expiration Date June 4, 2021
Application budgets should not exceed $499,999 direct costs per year. Within that limit, applications need to reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum project period is 5 years.